Successful Pamidronate Treatment of Osteogenesis Imperfecta Type III Infant with Multiple Fractures
1
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Osteogenesis imperfect (OI) is a generalized connective tissue disorder. We report the female neonate case with OI type III who showed severe bone deformities and fractures in utero. At birth, she showed multiple fractures in the clavicle, rib, femur, and wormian bone in the skull X-ray. We initiated pamidronate disodium infusion 30 mg/m2 in cycles of 3 consecutive days from when she was 4 days old, monthly for the first 3months and every 2 months thereafter without adverse effects.
Abstract
Osteogenesis imperfect (OI) is a generalized connective tissue disorder. We report the female neonate case with OI type III who showed severe bone deformities and fractures in utero. At birth, she showed multiple fractures in the clavicle, rib, femur, and wormian bone in the skull X-ray. We initiated pamidronate disodium infusion 30 mg/m2 in cycles of 3 consecutive days from when she was 4 days old, monthly for the first 3months and every 2 months thereafter without adverse effects.
참고문헌 (15)
- Marini JC, "Osteogenesis imperfecta, In Nelson Textbook of Pediatrics, 19th ed", pp.2437~2440 (2011), Saunders
- Sykes B, "Consistent linkage of dominantly inherited osteogenesis imperfecta to the type I collagen loci: COL1A1 and COL1A2", Am J Hum Genet, 46, pp.293~307 (1990)
- Barr DGD, "Disorders of bone, joints and connective tissue, In Forfar and Arneil’s Textbook of Pediatrics, 5th Ed", pp.1567~1570 (1998), Churchill Livingstone
- Mondal RK, "Osteogenesis imperfecta with bleeding diathesis", Indian J Pediatr, 70, pp.95~96 (2003)
- Rauch F, "Osteogenesis imperfecta", Lancet, 363, pp.1377~1385 (2004)
- Marini JC, "Positive linear growth and bone responses to growth hormone treatment in children with types III and IV osteogenesis imperfecta: high predictive value of the carboxyterminal propeptide of type I procollagen", J Bone Miner Res, 18, pp.237~243 (2003)
- Glorieux FH, "Cyclic administration of pamidronate in children with severe osteogenesis imperfecta", N Engl J Med, 339, pp.947~952 (1998)
- Aström E, "Beneficial effect of long term intravenous bisphosphonate treatment of osteogenesis imperfecta", Arch Dis Child, 86, pp.356~364 (2002)
- Lee YS, "Cyclic pamidronate infusion improves bone mineralisation and reduces fracture incidence in osteogenesis imperfecta", Eur J Pediatr, 160, pp.641~644 (2001)
- Wijewardena SK, "Bisphosphonate treatment for type III osteogenesis imperfecta in Lady Ridgeway Hospital, Colombo, Sri Lanka", Sri Lanka J Child Health, 39, pp.44~46 (2010)
- DiMeglio LA, "Two-year clinical trial of oral alendronate versus intravenous pamidronate in children with osteogenesis imperfecta", J Bone Miner Res, 21, pp.132~140 (2006)
- Sakkers R, "Skeletal effects and functional outcome with olpadronate in children with osteogenesis imperfecta: a 2-year randomized placebo-controlled study", Lancet, 363, pp.1427~1431 (2004)
- Falk MJ, "Intravenous bisphosphonate therapy in children with osteogenesis imperfecta", Pediatrics, 111, pp.573~578 (2003)
- Rauch F, "The effects of intravenous pamidronate on the bone tissue of children and adolescents with osteogenesis imperfecta", J Clin Invest, 110, pp.1293~1299 (2002)
- Jakubowska-Pietkiewicz E, "New trends in the treatment of osteogenesis imperfecta type III - own experience", Ortop Traumatol Rehabil, 10, pp.593~601 (2008)
